Kadmon Holdings shares were up over 10% pre-market Tuesday after the company unveiled positive interim results from its ongoing phase 2 clinical trial evaluating KD02, in patients with previously treated chronic graft-versus-host disease (“cGVHD”).
In a preliminary analysis, KD025 demonstrated a favorable safety and tolerability profile in all patients and an overall response rate (“ORR”) of 71%. cGVHD is a serious complication following allogeneic bone marrow or stem cell transplantation. “These positive interim findings indicate activity and a favorable safety profile of KD025 in cGVHD, a fatal disease with no approved therapies,” said John Ryan chief medical officer of Kadmon. “Steroids are the current standard therapy for cGVHD and have severe side effects associated with long-term use. We are pleased to see that the majority of patients in the first cohort have been able to reduce their steroid doses, indicating that KD025 potentially offers a well-tolerated treatment option for cGVHD patients.”